NCT03786692View on ClinicalTrials.gov

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2028

Conditions
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Interventions
DRUG

Arm A

Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab

DRUG

Arm B

Carboplatin + Pemetrexed + Bevacizumab

Trial Locations (1)

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Fox Chase Cancer Center

OTHER